Bioscan Research has raised $1 million in seed funding, giving the medical device startup fresh capital to expand its brain injury detection technology. The round was led by Unicorn India Ventures, an early-stage investment firm that backs technology-led startups.
This is an important funding story because Bioscan is not building a regular health app or hospital software tool. It is working on a medical device called CEREBO, which is designed to help doctors and emergency teams screen for brain injuries without cutting into the body or using harmful radiation.
For a country like India, where road accidents, falls and delayed access to advanced scans remain serious problems, a faster first-level screening tool can be useful. Bioscan’s idea is simple to understand. When a patient has a head injury, every minute matters. If doctors can spot warning signs early, they can decide who needs urgent care, CT scan priority or transfer to a better-equipped hospital.
What Bioscan Research does
Bioscan Research is a medical device startup focused on early brain injury detection. Its main product is CEREBO, a portable device that uses near-infrared light and machine learning to help screen for possible bleeding inside the skull.
Near-infrared light sounds technical, but the basic idea is not too hard. The device sends safe light through parts of the head and studies how that light is absorbed. Blood absorbs light differently, so an unusual pattern can suggest a possible internal bleed.
The device then uses software to read these patterns and support clinical decision-making. It does not replace a CT scan. Instead, it works more like an early warning and triage tool.
For example, imagine a patient reaches a small hospital after a road accident. The patient may look stable, but there is still a chance of internal bleeding. If a CT scanner is not nearby, a portable screening device can help the medical team decide whether the patient needs urgent transfer or closer observation.
Founders and startup journey
Bioscan Research was founded by Anupam Lavania and Shilpa Malik in 2017.
The company is based in Ahmedabad, Gujarat, and works in the medical device space. Its work sits at the crossing point of healthcare, electronics, optics and software. That matters because building a medical device is much harder than building a consumer gadget. It needs clinical testing, safety checks, manufacturing quality and regulatory approvals.
Why this $1 million funding matters
Bioscan plans to use the funding for market expansion, regulatory approvals, product improvement and intellectual property development. In plain words, the company wants to take CEREBO to more hospitals and markets, improve the device further, and protect its technology.
This kind of funding can be useful at the seed stage because medical devices need patient capital. A startup cannot simply build a product, launch it online and scale overnight. Hospitals want proof. Regulators want documentation. Doctors want accuracy. Buyers want service support.
That is why the money is not just for sales. It is also for the slower, less glamorous work that makes a medical device reliable.
The startup has also reportedly seen strong revenue growth over the past year and is targeting further growth in the next 12 months. For investors, this suggests that the product is not only a lab idea. It is moving toward wider real-world use.
Why brain injury screening needs better tools
Traumatic brain injury, often called TBI, can happen after road accidents, falls, sports injuries, workplace accidents or physical impact. The problem is that symptoms are not always obvious in the beginning.
A person may walk into a hospital, talk normally and still have bleeding inside the skull. In other cases, mild symptoms may be ignored until the condition becomes worse.
CT scans remain the standard tool for confirming many serious head injuries. But CT scanners are expensive, not always available in smaller centres, and cannot always be used immediately in crowded emergency departments. That gap creates space for point-of-care devices.
Point-of-care simply means the test can be done close to the patient, rather than waiting for a large machine or sending samples away. If CEREBO can help doctors decide faster, it may reduce delays in treatment.
Where CEREBO can be useful
CEREBO is designed for emergency rooms, ambulances, trauma centres, defence settings and smaller healthcare facilities where quick screening is important.
In a large hospital, it may help doctors decide which patient should go for CT first. In a rural or semi-urban setting, it may help identify patients who need urgent transfer. In defence or disaster-response situations, portability can be a major advantage.
The device may also be useful in public health settings where resources are limited. India has many places where advanced imaging is not available round the clock. A portable screening device cannot solve the whole problem, but it can help bridge the first decision-making gap.
Competitors and market landscape
Bioscan Research is working in a specialized area, so its competition is not the same as a typical consumer health startup. Its closest comparison comes from other brain injury screening devices and older near-infrared based tools such as Infrascanner, which has been used in some international markets.
The bigger competition is also the existing hospital workflow. Doctors already depend on CT scans, neurological exams and clinical judgment. For Bioscan to grow, it has to prove that CEREBO fits naturally into this workflow and gives useful information without slowing teams down.
In India, other healthtech and medtech startups are also building diagnostic tools, but Bioscan’s focus on non-invasive brain injury screening gives it a fairly distinct position.
What investors may be betting on
Unicorn India Ventures appears to be backing a product that solves a real medical problem, not just a convenience problem. Brain injury detection is a serious area, and hospitals need better ways to manage emergency cases.
The investor interest may also come from the fact that medical devices built in India can serve both domestic and global markets. If a product is affordable, portable and clinically useful, it can find demand in countries where access to large hospital infrastructure is uneven.
For Bioscan, the next challenge is execution. The company has to scale sales, handle approvals, keep product quality strong and win doctor trust. In healthcare, trust grows slowly. But once a product earns it, adoption can become meaningful.
Conclusion with key takeaways
Bioscan Research’s $1 million seed funding is a strong step for a startup working on a serious healthcare problem. Its CEREBO device aims to make early brain injury screening faster, simpler and more accessible, especially in places where CT access may be limited or delayed.
The company still has a long road ahead. Medical device startups must pass through clinical, regulatory and commercial tests before becoming mainstream. But the need is clear, and the product is aimed at a problem where time can change outcomes.
Key takeaways
- Bioscan Research raised $1 million in seed funding led by Unicorn India Ventures.
- The startup was founded by Anupam Lavania and Shilpa Malik.
- Its main product, CEREBO, screens for possible brain bleeding using near-infrared light and machine learning.
- The device is meant to support early triage, not replace CT scans.
- The funding will support expansion, regulatory approvals, product upgrades and IP creation.
Facts Input- Express Healthcare, Tech Observer, PubMed, India Science
Image Credit
Related
Discover more from Newskart
Subscribe to get the latest posts sent to your email.
